Candel Therapeutics Inc
CADLBuild a strategy around CADL
Candel Therapeutics Inc AI Insights
Informational only. Not investment advice.Snapshot
- Zero revenue (TTM) with 119.7M cash — ~3 years of runway at current -38.9M FCF burn rate, but 49M long-term debt adds pressure.[Cash and Equivalents]
- R&D spend of 30.5M (TTM) is 63% of total opex (48.2M), with G&A at only 4.7M — lean overhead for a clinical-stage biotech.[Research and Development]
- P/B ratio of 8.2x (TTM) on 51.9M equity with zero revenue — market pricing in binary clinical outcomes, not fundamentals.[P/B Ratio]
Watch Triggers
- Cash and Equivalents: Falls below 60M (18-month runway threshold) — Below 18 months of cash at current burn forces dilutive financing or partnership on weak terms.
- Research and Development: Quarterly R&D jumps >25% sequentially — Would signal late-stage trial ramp, accelerating burn and shortening runway to capital event.
- Issuance of Capital Stock: Any new equity issuance above 0 (currently 0 TTM) — First dilutive raise signals management views runway as insufficient for next catalyst.
Bull Case
119.7M cash with only 9M current liabilities (TTM) gives 13.3x current coverage — ample runway to reach clinical catalysts without immediate dilution.
R&D-heavy cost structure (63% of opex TTM) with minimal G&A (4.7M) signals capital efficiency; 428M market cap prices optionality on pipeline.
Bear Case
Zero revenue with -38.9M FCF (TTM) and 49M debt means equity holders face dilution or subordination; debt/equity at 0.94x is high for a pre-revenue biotech.
8.2x P/B (TTM) on a company with no revenue and negative ROE of -64.6% — valuation is entirely speculative on binary trial outcomes.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage CADL's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Cash runway extends ~3 years but debt maturity and trial outcomes will force a capital event before 2029.
- FCF burn of -38.9M (TTM) against 119.7M cash
- 49M total debt with 48.6M long-term creates refinancing risk
- Zero revenue means dilution or partnership is inevitable
13.5M gain on investment securities (TTM) masked true operating burn; normalized losses are deeper.
- Gain on Sale of Security of -13.5M (unusual item) inflated net income
- Operating cash flow -10.6M vs FCF -38.9M divergence signals timing items
- Net income -38.2M still understates opex trajectory if R&D scales
Valuation Context
Caveats
CADL Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$581.03M | — | ||
$435.47M | — | ||
0.00 | — | ||
$0 | — | ||
$0.00 | — | ||
0% | — | ||
0% | — | ||
$0 | — | ||
0% | — | ||
Beta 5Y (Monthly) | unknown | — |
CADL Dividend History
CADL Stock Splits
CADL SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
05/14/26 | 03/31/26 | 10-Q | |
03/12/26 | 12/31/25 | 10-K | |
11/13/25 | 09/30/25 | 10-Q | |
08/14/25 | 06/30/25 | 10-Q | |
05/13/25 | 03/31/25 | 10-Q | |
03/13/25 | 12/31/24 | 10-K | |
11/14/24 | 09/30/24 | 10-Q | |
08/13/24 | 06/30/24 | 10-Q | |
05/14/24 | 03/31/24 | 10-Q | |
03/28/24 | 12/31/23 | 10-K | |
11/09/23 | 09/30/23 | 10-Q | |
08/10/23 | 06/30/23 | 10-Q | |
05/11/23 | 03/31/23 | 10-Q | |
03/30/23 | 12/31/22 | 10-K | |
11/10/22 | 09/30/22 | 10-Q | |
08/05/22 | 06/30/22 | 10-Q | |
05/12/22 | 03/31/22 | 10-Q | |
03/29/22 | 12/31/21 | 10-K | |
11/12/21 | 09/30/21 | 10-Q | |
09/08/21 | 06/30/21 | 10-Q | |
07/28/21 | 03/31/21 | 424B4 | |
07/28/21 | 12/31/20 | 424B4 | |
11/12/21 | 09/30/20 | 10-Q | |
09/08/21 | 06/30/20 | 10-Q | |
07/28/21 | 03/31/20 | 424B4 |